|

Anti-Müllerian Hormone in Breast Cancer Clinical Practice

RECRUITINGSponsored by Masaryk Memorial Cancer Institute
Actively Recruiting
SponsorMasaryk Memorial Cancer Institute
Started2025-11-20
Est. completion2027-06
Eligibility
Age20 Years – 55 Years
SexFEMALE
Healthy vol.Accepted

Summary

This study aims to evaluate serum anti-Müllerian hormone (AMH) levels and complementary hormonal parameters, including follicle-stimulating hormone (FSH), estradiol, thyroid-stimulating hormone (TSH), and free thyroxine (fT4), in women with breast cancer and healthy female controls. The study will generate preliminary real-world data on AMH and related hormonal parameters and assess the feasibility of implementing AMH testing into routine clinical practice.

Eligibility

Age: 20 Years – 55 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Women aged 20-55 years.
* Patients with a diagnosis of breast cancer at any of the specified stages of treatment or follow-up, or healthy female volunteers.
* Blood sampling as part of routine clinical care (breast cancer patients) or willingness to undergo a single blood draw (healthy volunteers).

Exclusion Criteria:

* Inability or unwillingness to participate in the study.

Conditions2

Breast CancerCancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.